85468-01-5

Basic information

• Product Name: GUSPERIMUS 3HCL
• Synonyms: GUSPERIMUS 3HCL;NKT-01TRIHYDROCHLORIDEDIHYDRATE;Gusperimus HCl;Gusperimus trihydrochloride;Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-, trihydrochloride;Heptanamide, 7-((aminoiminomethyl)amino)-N-(2-((4-((3-aminopropyl)amino)butyl)amino)-1-hydroxy-2-oxoethyl)-, trihydrochloride, (+-)-;Spanidin
• CAS NO: 85468-01-5
• Molecular Formula: C17H37N7O3.3ClH
• Molecular Weight: 496.908
• Mol File: 85468-01-5.mol

Chemical Properties

• Boiling Point: 740.1°C at 760 mmHg
• Flash Point: 401.4°C
• Appearance: /
• Vapor Pressure: 2.76E-25mmHg at 25°C
• CAS DataBase Reference: GUSPERIMUS 3HCL(CAS DataBase Reference)
• NIST Chemistry Reference: GUSPERIMUS 3HCL(85468-01-5)
• EPA Substance Registry System: GUSPERIMUS 3HCL(85468-01-5)

Safety Data

• Hazardous Substances Data: 85468-01-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
GUSPERIMUS 3HCL is used as an immunosuppressive agent for managing the immune response in organ transplantation procedures. Its ability to prevent and treat graft-vs.-host disease makes it a valuable asset in ensuring the success of transplants and reducing the risk of rejection.
Used in Immunology Research:
In the field of immunology, GUSPERIMUS 3HCL serves as a research tool to study the mechanisms of immune response and the development of new therapies for autoimmune diseases and other conditions where immune system modulation is necessary. Its effectiveness in suppressing the immune system allows researchers to gain insights into the complex interactions between immune cells and potential targets for intervention.

InChI:InChI=1/C17H37N7O3.3ClH/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20;;;/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23);3*1H/t16-;;;/m0.../s1

Upstream product

• 110-94-1 1,5-pentanedioic acid 
• 181484-26-4 methyl [(7-azidoheptanoyl)amino](benzyloxy)acetate 
• 181484-31-1 (7-azido-heptanoylamino)-benzyloxy-acetic acid 
• 181483-85-2 7-azidoheptanamide 
• 343626-02-8 benzyl 21-[(benzyloxy)carbonyl]amino-11-(benzyloxy)-4-[(benzyloxy)carbonyl]-10,13,23-trioxo-25-phenyl-24-oxa-4,9,12,20,22-pentaazapentacos-21-en-1-yl carbamate 

Relevant articles and documents

A new efficient synthesis of the immunosuppressive agent (±)-15-deoxyspergualin

(±)-15-Deoxyspergualin is a new promising immunosuppressive agent, recently marketed in Japan for the control of cortico-resistant acute renal graft rejection. We describe here a nine-step synthesis starting from 7-bromoheptanenitrile and N1,N4-bis(benzyloxycarbonyl)spermidine, suitable for the production of multigram quantities of this unstable highly polar compound with an 18% overall yield. Furthermore, it opens the way for the synthesis of α-hydroxyglycine analogues.

(-)-15-Deoxyspergualin: A new and efficient enantioselective synthesis which allows the definitive assignment of the absolute configuration

(±)-15-Deoxyspergualin (DSG) has recently been marketed in Japan for the control of corticoresistant acute renal graft rejection. A nine-step total synthesis of its eutomer ((-)-DSG) 2 has been developed starting from 7-bromoheptanenitrile 3 and N1,N4-bis(benzyloxycarbonyl)spermidine. The use of a chiral α-alkylbenzyl group to protect the hydroxyl of the α- hydroxyglycine moiety allowed its chromatographic resolution and afforded a practical access to 2 with a high optical purity and a 7% overall yield. Moreover, X-ray structure analysis of the key crystalline intermediate 7b definitely confirmed the previously proposed absolute configuration of 2.

Method for producing glyoxylylspermidine and the use thereof for the production of 15-deoxy spergualin-related compounds

Glyoxylylspermidine, an intermediate for 15-deoxyspergualin-related compounds, is prepared in an oxidative cleavage reaction.

N-[4-(3-aminopropyl)-aminobutyl]-2-(ω-guanidino-fatty-acid-amido)-2-substituted-ethanamide and salt thereof

N-[4-(3-Aminopropyl)aminobutyl]-2-(ω-guanidino-fatty acid-amido)-2-substituted-ethanamides represented by the general formula STR1 wherein Y represents --(CH2 --CH2 --, --CH=CH or STR2 R represents a hydrogen atom, an alkyl group of 1 to 4 carbon atoms which may have a hydroxyl group as substituent, or a benzyl group, and n is an integer of from 1 to 8, provided that when Y is STR3 and n is 4, R represents the groups other than the hydrogen atom; a salt thereof having antitumor activity in experimental animal tumors and a process for the preparation thereof is provided.